Current Report Filing (8-k)
10 January 2023 - 10:23PM
Edgar (US Regulatory)
0001769804
false
0001769804
2023-01-09
2023-01-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
January 9, 2023
AUGMEDIX, INC.
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-40890 |
|
83-3299164 |
|
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
111 Sutter Street, Suite 1300, San Francisco, California
94104
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including
area code: (888) 669-4885
N/A
(Former name or former address, if changed since
last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, $0.0001 par value per share |
|
AUGX |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02. Results of Operations and Financial
Condition
On January 9, 2023, Augmedix, Inc., a Delaware corporation, announced
its preliminary financial results for the fourth quarter ended December 31, 2022. The press release announcing the release of preliminary
financial results is furnished as Exhibit 99.1 and is incorporated herein by reference.
The information provided in this Item 2.02,
including Exhibit 99.1, is intended to be “furnished” and shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended,
or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
AUGMEDIX, INC. |
| |
|
|
| Dated: January 10, 2023 |
By: |
/s/ Paul Ginocchio |
| |
|
Paul Ginocchio |
| |
|
Chief Financial Officer |
Augmedix (NASDAQ:AUGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Augmedix (NASDAQ:AUGX)
Historical Stock Chart
From Apr 2023 to Apr 2024
